Charles River Laboratories International (NYSE:CRL) Sets New 12-Month Low – What’s Next?

Charles River Laboratories International, Inc. (NYSE:CRL)’s share price hit a new 52-week low on Wednesday . The company traded as low as $175.61 and last traded at $178.38, with a volume of 1867915 shares trading hands. The stock had previously closed at $190.14.

Analyst Upgrades and Downgrades

CRL has been the subject of several research analyst reports. UBS Group upped their price target on shares of Charles River Laboratories International from $240.00 to $250.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. StockNews.com cut Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Thursday, November 7th. CLSA lowered Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price target on the stock. in a research note on Monday, November 18th. Robert W. Baird lowered their price objective on Charles River Laboratories International from $191.00 to $190.00 and set a “neutral” rating for the company in a research note on Friday, September 20th. Finally, TD Cowen lifted their target price on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a research report on Monday, November 11th. Three analysts have rated the stock with a sell rating, eleven have assigned a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, Charles River Laboratories International currently has an average rating of “Hold” and an average price target of $214.00.

Charles River Laboratories International Stock Performance

The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.14 and a current ratio of 1.48. The stock’s 50 day moving average price is $192.56 and its 200 day moving average price is $198.95. The company has a market capitalization of $8.47 billion, a P/E ratio of 20.73, a price-to-earnings-growth ratio of 6.62 and a beta of 1.38.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, beating analysts’ consensus estimates of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The business had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $975.99 million. During the same quarter in the prior year, the firm posted $2.72 earnings per share. The business’s quarterly revenue was down 1.6% compared to the same quarter last year. As a group, equities analysts expect that Charles River Laboratories International, Inc. will post 10.18 EPS for the current year.

Insider Buying and Selling

In other Charles River Laboratories International news, Director Richard F. Wallman sold 6,621 shares of the business’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $216.12, for a total value of $1,430,930.52. Following the transaction, the director now directly owns 12,386 shares of the company’s stock, valued at approximately $2,676,862.32. The trade was a 34.83 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.30% of the stock is currently owned by insiders.

Institutional Trading of Charles River Laboratories International

Several hedge funds have recently modified their holdings of CRL. Versant Capital Management Inc boosted its stake in Charles River Laboratories International by 1,071.4% during the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock worth $30,000 after acquiring an additional 150 shares in the last quarter. Wolff Wiese Magana LLC acquired a new position in shares of Charles River Laboratories International during the third quarter valued at about $32,000. Pinnacle Bancorp Inc. boosted its position in shares of Charles River Laboratories International by 52.0% during the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock worth $35,000 after purchasing an additional 65 shares in the last quarter. Assetmark Inc. grew its stake in shares of Charles River Laboratories International by 1,153.3% in the 3rd quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock valued at $37,000 after buying an additional 173 shares during the period. Finally, ORG Wealth Partners LLC bought a new stake in Charles River Laboratories International in the 4th quarter valued at about $56,000. Institutional investors own 98.91% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).